$1700 | SAVE $300 | Single User
$3400 | SAVE $600 | Site License
$5100 | SAVE $900 | Enterprise License

Coronary Artery Disease - Pipeline Review, H1 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2017
[Lowest Price Guaranteed: $1,700]

Published by Global Markets Direct: 08 Mar 2017 | 47435 | In Stock
Related Topics: Healthcare

Introduction

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2017, provides an overview of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline landscape.

Coronary artery disease (CAD) is the most common type of heart disease. CAD happens when the arteries that supply blood to heart muscle become hardened and narrowed. This is due to the buildup of cholesterol and other material, called plaque, on their inner walls. This buildup is called atherosclerosis. As it grows, less blood can flow through the arteries. As a result, the heart muscle can't get the blood or oxygen it needs. This can lead to chest pain (angina) or a heart attack. Most heart attacks happen when a blood clot suddenly cuts off the hearts' blood supply, causing permanent heart damage. The most common symptom of coronary artery disease is angina, or chest pain. Other symptoms include shortness of breath, palpitations, a faster heartbeat, weakness or dizziness, nausea and sweating.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 3, 17, 7, 18 and 1 respectively. Similarly, the Universities portfolio in IND/CTA Filed and Discovery stages comprises 1 and 1 molecules, respectively.

Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular).

- The pipeline guide reviews pipeline therapeutics for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
for Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2017

  • Table of Contents

    Table of Contents 2

    List of Tables 5

    List of Figures 6

    Introduction 7

    Global Markets Direct Report Coverage 7

    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Overview 8

    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Development 9

    Pipeline Overview 9

    Pipeline by Companies 10

    Pipeline by Universities/Institutes 14

    Products under Development by Companies 15

    Products under Development by Universities/Institutes 18

    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Assessment 19

    Assessment by Target 19

    Assessment by Mechanism of Action 22

    Assessment by Route of Administration 25

    Assessment by Molecule Type 27

    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Companies Involved in Therapeutics Development 29

    advanceCor GmbH 29

    Akcea Therapeutics Inc 29

    Amarantus Bioscience Holdings Inc 30

    AnGes MG Inc 30

    Arena Pharmaceuticals Inc 31

    Ascendia Pharmaceuticals LLC 31

    AstraZeneca Plc 32

    Athera Biotechnologies AB 32

    Bayer AG 33

    Biscayne Pharmaceuticals Inc 33

    Capricor Therapeutics Inc 34

    Cardiome Pharma Corp 34

    CardioVascular BioTherapeutics Inc 35

    Cerenis Therapeutics Holding SA 35

    CSL Ltd 36

    Esperion Therapeutics Inc 36

    Gilead Sciences Inc 37

    HitGen LTD 37

    Human Stem Cells Institute 38

    Japan Tobacco Inc 38

    Juventas Therapeutics Inc 39

    Lee's Pharmaceutical Holdings Ltd 39

    LipimetiX Development Inc 40

    Lonestar Heart Inc 40

    MedImmune LLC 41

    Merck & Co Inc 41

    Nuo Therapeutics Inc 42

    Pfizer Inc 42

    Pharmahungary Group 43

    Proteon Therapeutics Inc 43

    Resverlogix Corp 44

    Tasly Pharmaceutical Group Co Ltd 44

    The Medicines Company 45

    Verseon Corp 45

    VESSL Therapeutics Ltd 46

    ViroMed Co Ltd 46

    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Drug Profiles 47

    4-WF - Drug Profile 47

    AEM-28 - Drug Profile 48

    AEM-2802 - Drug Profile 50

    ALD-201 - Drug Profile 51

    alprostadil - Drug Profile 53

    AMRS-001 - Drug Profile 54

    anacetrapib - Drug Profile 63

    apabetalone - Drug Profile 65

    AZD-5069 - Drug Profile 77

    AZD-5718 - Drug Profile 79

    beperminogene perplasmid - Drug Profile 80

    Biologics for Acute Coronary Syndrome - Drug Profile 86

    BIS-5409 - Drug Profile 87

    bivalirudin - Drug Profile 88

    cangrelor tetrasodium - Drug Profile 89

    CAP-1002 - Drug Profile 93

    CAP-2003 - Drug Profile 99

    CER-001 - Drug Profile 101

    clopidogrel bisulphate - Drug Profile 105

    COR-2 - Drug Profile 106

    Cryocell - Drug Profile 107

    CSL-112 - Drug Profile 108

    CVBT-141H - Drug Profile 110

    dalcetrapib - Drug Profile 111

    Gemacell - Drug Profile 115

    Gene Therapy to Activate Vascular Endothelial Growth Factor for Coronary Artery Disease - Drug Profile 116

    IONIS-APOARX - Drug Profile 117

    JVS-100 - Drug Profile 120

    MEDI-6012 - Drug Profile 125

    MultiGeneAngio - Drug Profile 128

    MZ-004 - Drug Profile 129

    Neovasculgen - Drug Profile 131

    PC-mAb - Drug Profile 132

    PF-06282999 - Drug Profile 135

    PMC-6 - Drug Profile 136

    PR-15 - Drug Profile 137

    Proteins for Ischemic Heart Disease - Drug Profile 139

    ranolazine ER - Drug Profile 140

    Recombinant Protein for Cardiovascular Diseases - Drug Profile 143

    Rejuveinix - Drug Profile 144

    rivaroxaban - Drug Profile 145

    Small Molecules to Inhibit Gamma Butyrobetaine for Coronary Heart Disease - Drug Profile 161

    Small Molecules to Inhibit PCSK9 for Acute Coronary Syndrome and Atherosclerosis - Drug Profile 162

    Small Molecules to Inhibit Thrombin for Cardiovascular Diseases - Drug Profile 163

    temanogrel hydrochloride - Drug Profile 165

    tirofiban hydrochloride - Drug Profile 167

    TSL-0202 - Drug Profile 168

    vericiguat - Drug Profile 169

    VM-202 - Drug Profile 171

    vonapanitase - Drug Profile 175

    ZK-001 - Drug Profile 180

    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects 182

    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products 188

    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Product Development Milestones 190

    Featured News & Press Releases 190

    Appendix 202

    Methodology 202

    Coverage 202

    Secondary Research 202

    Primary Research 202

    Expert Panel Validation 202

    Contact Us 202

    Disclaimer 203

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

47435 | GMDHC9017IDB

Number of Pages

207

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! Global Coronary Artery Disease Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Nov 2016 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Global Coronary Artery Disease Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! EpiCast Report: Acute Coronary Syndrome - Epidemiology Forecast to 2025
EpiCast Report: Acute Coronary Syndrome - Epidemiology Forecast to 2025SummaryAcute coronary syndrom...
08 Aug 2016 by Global Data USD $3,396 (normally
USD $3,995)
More Info
SAVE 15% today! Coronary Stenosis Global Clinical Trials Review, H2, 2016
Coronary Stenosis Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial report, ...
29 Jul 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Occlusive Coronary Artery Disease Global Clinical Trials Review, H2, 2016
Occlusive Coronary Artery Disease Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinica...
29 Jul 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Percutaneous Transluminal Coronary Angioplasty Drug Eluting Balloon (DEB) Catheters - Medical Devices Pipeline Assessment, 2016
Percutaneous Transluminal Coronary Angioplasty Drug Eluting Balloon (DEB) Catheters - Medical Device...
01 Jun 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Coronary Artery Bypass Graft Surgery - Medical Devices Pipeline Assessment, 2016
Coronary Artery Bypass Graft Surgery - Medical Devices Pipeline Assessment, 2016SummaryGlobalData's ...
15 Apr 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Global Clinical Trials Review, H2, 2015
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Global Clinical Trials Review, H2, 20...
23 Dec 2015 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Coronary Disease Global Clinical Trials Review, H2, 2015
Coronary Disease Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial report, “...
23 Dec 2015 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Percutaneous Coronary Intervention Global Clinical Trials Review, H2, 2015
Percutaneous Coronary Intervention Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinic...
23 Dec 2015 by Global Data USD $2,125 (normally
USD $2,500)
More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2017 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...